Investigating how genetics affect response to oral semaglutide in prediabetes and obesity
Official title: Genetics of the Acute Response to Oral Semaglutide (GAROS)
Run by Medical University of Bialystok · NCT05340868 · Data updated 2026-11-12
This study is testing how genetics affect how well people with prediabetes and obesity respond to a three-month treatment with oral semaglutide.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Medical University of Bialystok Academic / other |
| Locations | 1 site (Bialystok, Podlaskie Voivodeship) |
| Status | Recruiting |
| Started | September 1, 2022 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | March 26, 2025 |
| Trial ID | NCT05340868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with a BMI over 30 or over 27 with prediabetes.
✕Probably not a fit
Patients with serious chronic diseases or those who have undergone bariatric surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study explores the genetic factors influencing the response to a three-month treatment with oral semaglutide in individuals with prediabetes and obesity. Participants will undergo various assessments, including blood tests, glucose tolerance tests, and body composition analysis, to evaluate metabolic changes and hormonal responses. Additionally, genome-wide genotyping will be performed, and a subset of participants will have muscle and fat biopsies, along with MRI assessments of fat content in the liver, muscle, and pancreas. The goal is to understand how genetic variations impact treatment outcomes.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies for prediabetes and obesity based on genetic profiles.
How similar studies have gone: While pharmacogenetic studies are common, this specific approach to semaglutide response in prediabetes is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent was given before any study-related action on the subject. * Age: 18-65 years old * Body mass index (BMI) \>30 kg/m2 or \>27 kg/m2 when accompanied by prediabetes, diagnosed according to the criteria of the American Diabetes Association Exclusion Criteria: * Patients diagnosed with a serious chronic disease, including: * Ischemic heart disease * Heart failure (NYHA class III-IV) * Severe renal insufficiency (eGFR \<30 ml/min) * Severe liver diseases * Inflammatory bowel disease * Diabetic gastroparesis * Cancer - currently or in the last five years prior to screening * Chronic obstructive pulmonary disease * History of mental illness, major depression or other severe mental disorders * Use of any medications with clinically-proven significant weight gain or loss effects * History of undergoing bariatric surgery or other surgery involving the stomach that could affect the absorption of the study drug (according to the investigator's opinion) * History of idiopathic acute pancreatitis * A family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid cancer * For women - pregnancy, breastfeeding or planning pregnancy. * Women of childbearing age who are not using highly effective methods of contraception * Known or suspected hypersensitivity to the test product
Where it's running
-
Clinical Research Centre, Medical University of Bialystok
Bialystok, Podlaskie Voivodeship, Poland Recruiting
Study contacts
- Principal investigator: Lukasz Szczerbinski, MD, PhD — Clinical Research Centre, Medical University of Bialystok
- Study coordinator: Lukasz Szczerbinski, MD, PhD
- Email: lukasz.szczerbinski@umb.edu.pl
- Phone: +48858318150
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-Intensity Interval Training vs. Continuous Endurance Training in Prediabetes
This study tests whether short bursts of intense exercise or steady, longer workouts can improve blood sugar control and fitness in people with prediabetes.
-
Lowering insulin to reduce liver fat production
This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.
-
Pre-screening to identify adults who may be eligible for future metabolic and mental health opportunities.
This prescreening will see if adults with metabolic conditions or mental health disorders qualify for upcoming clinical opportunities by collecting health history, basic tests, and a doctor interview.
-
Hands-on nutrition demonstrations added to the Diabetes Prevention Program for people with prediabetes
This project will test whether adding a 7-week series of healthy cooking and nutrition demos to the Diabetes Prevention Program helps adults at risk for prediabetes stay engaged and put healthy eating into daily life.
-
Combining exercise with intermittent fasting to improve eye dryness in pre-diabetic psoriasis patients
This study is testing if combining exercise with intermittent fasting can help reduce eye dryness in people with psoriasis and prediabetes.
-
Couple-based lifestyle intervention to prevent type 2 diabetes
This study is testing if a lifestyle program for couples can help high-risk adults prevent type 2 diabetes by encouraging healthy changes together.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.